Mycoplasma Testing Market to grow at a CAGR of 10.20% during 2026 to 2035; Driven by Increasing Demand for Mycoplasma Testing and Growing Focus on Quality Control in Biopharmaceutical and Healthcare Applications

Mycoplasma Testing Market Highlights

Mycoplasma Testing Market size was valued at USD 1.21 Billion in 2025, and the market is projected to grow from USD 1.35 Billion in 2026 to USD 3.52 Billion by 2035, registering a CAGR of 10.20% during the forecast period 2026–2035.

Regional Analysis

Geographically, the Americas is expected to dominate the global market owing to the presence of well-established players and growth in pharmaceutical and medical device companies.
Europe is expected to hold the second largest position in the global market. Asia-Pacific is expected to be the fastest growing market owing to the increasing adoption of the technologies. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global market.

Segmentation

The global mycoplasma testing market has been segmented into product, Technique, application, and end user.
Based on product, market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to account for the largest share and fastest growing segment of the global market in 2025.

Based on technique, market is segmented into Enzyme-based, PCR, ELISA, Direct Assay, Indirect Assay, Others.

Based on application, has been segmented into cell line and cell therapy testing, virus testing, row material testing, lot release testing, and others.

Based on end user, has been segmented into pharmaceutical and biological manufacturing, contract research organizations, cell banks, and others.

Key Players

Some of the prominent players in the global mycoplasma testing market are Charles River Laboratories, Inc., Merck KGaA, Lonza Group Ltd, Roche Diagnostics, SGS S.A., American Type Culture Collection, Invivogen, Wuxi Apptec, Promocell GmbH, and Thermo Fisher Scientific Inc.